EGFR mutations are associated with favorable intracranial response and progression-free survival following brain irradiation in non-small cell lung cancer patients with brain metastases

Hsin-Lun Lee¹, Tao-Sang Chung¹,³†, Lai-Lei Ting⁴, Jo-Ting Tsai⁵, Shang-Wen Chen⁶, Jeng-Fong Chiou⁴, Henry Wing-Cheung Leung¹ and H Eugene Liu²,⁷*

Abstract

Background: The presence of epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer (NSCLC) is associated with increased radiosensitivity in vitro. However, the results from clinical studies regarding the radiosensitivity in NSCLC with mutant EGFR are inconclusive. We retrospectively analyzed our NSCLC patients who had been regularly followed up by imaging studies after irradiation for brain metastases, and investigated the impact of EGFR mutations on radiotherapy (RT).

Methods: Forty-three patients with brain metastases treated with RT, together with EGFR mutation status, demographics, smoking history, performance status, recursive partitioning analysis (RPA) class, tumor characteristics, and treatment modalities, were included. Radiological images were taken at 1 to 3 months after RT, and 3 to 6 months thereafter. Radiographic response was evaluated by RECIST criteria version 1.1 according to the intracranial images before and after RT. Log-rank test and Cox regression model were used to correlate EGFR mutation status and other clinical features with intracranial radiological progression-free survival (RPFS) and overall survival (OS).

Results: The median follow-up duration was 15 months. Patients with mutant EGFR had higher response rates to brain RT than those with wild-type EGFR (80% vs. 46%; \( p = 0.037 \)). Logistic regression analysis showed that EGFR mutation status is the only predictor for treatment response (\( p = 0.032 \)). The median intracranial RPFS was 18 months (95% CI = 8.33-27.68 months). In Cox regression analysis, mutant EGFR (\( p = 0.025 \)) and lower RPA class (\( p = 0.026 \)) were associated with longer intracranial RPFS. EGFR mutation status (\( p = 0.061 \)) and performance status (\( p = 0.076 \)) had a trend to predict OS.

Conclusions: Mutant EGFR in NSCLC patients is an independent prognostic factor for better treatment response and longer intracranial RPFS following RT for brain metastases.

Keywords: Epidermal growth factor receptor, Non-small cell lung cancer, Brain metastases, Radiotherapy
Background

Non-small cell lung cancer (NSCLC) is the leading cause of mortality from cancer worldwide and the most common cancer responsible for brain metastases [1,2]. In NSCLC patients with brain metastases, radiotherapy (RT), the cornerstone of treatment, has yielded response rates of 50% to 75% for intracranial lesions [3]. Many prognostic factors have been explored in patients with brain metastases [4-12] including age, performance status, control of primary tumor, extent of extracranial disease, primary site of cancer, number of brain metastases, and treatment modalities. These parameters have been incorporated in commonly used indices in radiation oncology such as the Radiation Therapy Oncology Group (RTOG) recursive partitioning analysis (RPA) class and the Graded Prognostic Assessment (GPA). In addition, incorporation of biomarkers such as the expression level of epidermal growth factor receptor (EGFR), vascular endothelial growth factor, and cyclooxygenase-2 has also been correlated with treatment outcome after RT [13]. Among these biomarkers, amplification of EGFR has been extensively studied and is regarded as a poor prognostic factor in cancer [13-16]. In contrast to the radiosensitivity conferred by EGFR overexpression, the radioresensity of lung cancer cells with mutant EGFR has been demonstrated in vitro [17]. NSCLC cell lines with EGFR mutations are more sensitive to radiation, evidenced by increased apoptosis, than those with wild-type EGFR. However, prior clinical studies [18,19] attempting to investigate the relationship between EGFR mutations and radiosensitivity in NSCLC patients with brain metastases did not reach unanimous conclusions, mostly due to the lack of coordinated follow-up. Therefore, detailed analysis on the response of brain metastases to RT is imperative to clarify the role of EGFR mutations in NSCLC. We retrospectively analyzed our NSCLC patients who had been regularly followed up by imaging studies after irradiation for brain metastases, and investigated the impact of EGFR mutations on RT.

Methods

Patient eligibility

We reviewed 246 NSCLC patients who underwent EGFR mutation testing and received cancer treatment at Wan Fang Hospital and Taipei Medical University Hospital between April 2003 and January 2011. Of them, 134 patients were identified to have brain metastases. The presence of EGFR mutations was detected by either direct sequencing or the methods described previously [20]. This study proposal was approved by our institutional review board for the use of the patients’ pathology, medical records, and radiological images. The inclusion criteria for the analysis were as follows: (1) conventional brain RT as the only intracranial treatment; and (2) consecutive brain imaging follow-up 1 to 3 months after RT, and 3 to 6 months thereafter. Either contrast-enhanced brain magnetic resonance imaging (MRI) or computed tomography (CT) was required for assessment of intracranial tumors. A total of 43 eligible patients were enrolled into this study. The histology for most patients (n = 40) was adenocarcinoma, whereas 1 patient had adenosquamous carcinoma and 2 patients had poorly differentiated carcinoma.

Clinical characteristics such as age, gender, smoking history, performance status according to the Eastern Cooperative Oncology Group (ECOG), RPA class, extent of disease and the duration of EGFR tyrosine kinase inhibitor (TKI) therapy of each patient were collected by reviewing their medical records. Patients were stratified into RPA prognostic class (I, II, or III) based on the RTOG classification, which consists of age, performance status, control of primary tumor, and presence of extracranial metastases [6]. Controlled primary tumor was defined as no evidence of extracranial disease progression within 1 month before brain RT. Tumor characteristics, including number, size, and presence of hemorrhage, were evaluated on the basis of the pre- and post-treatment intracranial radiological images. Cause of death was determined by the symptoms at last follow-up and/or radiological images within 3 months of death.

RT and assessment of RT response

The standard treatment used for brain irradiation in this study was whole brain RT with 30 to 40 Gy in 10–20 fractions. Seventeen patients (40%) had local boost to tumor sites up to 50–60 Gy. The radiographic response of intracranial tumors was assessed using the Response Evaluation Criteria in Solid Tumors (RECIST) guideline version 1.1 [21] by comparing the post-treatment intracranial radiological images. Any in-field tumor progression or the appearance of new malignant lesions denoted progressive disease. A responder was defined as a combination of complete and partial response. Treatment-associated toxicities were scored according to the Common Terminology Criteria for Adverse Events version 3.0 [22].

Statistical analysis

Categorical data are presented as number (percentage), and continuous data are reported as mean ± standard deviation. Comparison of categorical variables between the mutant and wild-type EGFR groups was carried out by Fisher’s exact test and comparison of continuous variables was performed by independent sample t-test. Multivariable logistic regression analysis was used to examine the impact of variables on response rate.

The intracranial radiological progression-free survival (RPFS) was counted from the first day of brain RT to
the date of radiological progression or the last radiological documentation of the intracranial disease status. The overall survival (OS) was measured from the first day of brain RT to the date of death or last follow-up. We used the Kaplan–Meier method to calculate the RPFS and the OS. The log-rank test and Cox regression analysis were performed to explore the impact of variables on survival rate. The scheme of multivariable regression models (both logistic and Cox models) was as follows: a series of univariate (unadjusted) regression analyses were performed, and those variables whose \( p \) value is less than 0.1 in the univariate analyses were then included in the multivariable stepwise logistic regression analyses. Statistical significance was defined as a two-sided \( p \) value of <0.05. All analyses were carried out using SPSS statistical software (SPSS 15.0; SPSS Inc., Chicago, IL, USA).

**Results**

**Patient and tumor characteristics**

Of the 43 patients, 30 (70%) had EGFR mutations (15 had exon 19 deletions and 15 had exon 21 L858R point mutation). The patient demographics and tumor characteristics together with EGFR mutation status are listed in Table 1. Consistent with prior studies [23-25], the proportion of females and never-smokers was higher in patients with mutant EGFR (57% and 73%, respectively). The size of the largest lesion was significantly larger in patients with mutant EGFR (24.51 ± 11.74 mm) than those with the wild-type (16.45 ± 5.89 mm) (\( p = 0.024 \)). Hemorrhagic brain metastases (\( n = 11 \)) were observed only in patients with EGFR mutations. Of all patients, nineteen (44%) received EGFR TKI (14 received erlotinib and 5 received gefitinib) during the period of brain RT. The median duration of EGFR TKI therapy in patients with mutant EGFR (\( n = 15 \)) was 215 days (range, 25–412 days), whereas that in patients with the wild-type (\( n = 4 \)) was 32.5 days (range, 11–104 days). Due to limited numbers in the wild-type group, statistical analysis was not performed.

**Radiographic response to RT**

Of the 43 patients, 5 had a complete response and 25 had a partial response to RT. The overall response rate was 70%. The rest of the patients either remained stationary in tumor size (\( n = 11 \)) or had progressive intracranial lesions (\( n = 2 \)). The response rate was significantly higher in patients with EGFR mutations than those with the wild-type (80% vs. 46%; \( p = 0.037 \), Additional file 1: Table S1). Table 2 shows the association between clinical features and radiographic response to brain RT. Multivariable analyses revealed that EGFR mutation status is the only predictor for treatment response (odds ratio: 4.67, 95% confidence interval [CI]:

### Table 1 Clinical characteristics of non-small cell lung cancer patients with brain metastases treated with brain RT stratified by EGFR mutation status

| Characteristics          | Total \((N = 43)\) | EGFR mutation status | \( P \) |
|--------------------------|-------------------|----------------------|--------|
|                          |                   | Positive \((n = 30)\) | Negative \((n = 13)\) |
| Age, years               |                   |                      | 0.332  |
| Median (range)           | 59 (35-83)        |                      |        |
| <60                      | 22 (51)           | 17 (57)              | 5 (38) |
| ≥60                      | 21 (49)           | 13 (43)              | 8 (62) |
| Gender                   |                   |                      | 0.054  |
| Female                   | 20 (47)           | 17 (57)              | 3 (23) |
| Male                     | 23 (53)           | 13 (43)              | 10 (77) |
| Smoking history          |                   |                      | 0.043  |
| Never                    | 27 (63)           | 22 (73)              | 5 (38) |
| Ever                     | 16 (37)           | 8 (27)               | 8 (62) |
| ECOG performance status  | 1.60±0.88         | 1.60±0.89            | 1.62±0.87 | 0.959 |
| RPA class                |                   |                      | 1.000  |
| Class I                  | 5 (12)            | 4 (13)               | 1 (8) |
| Class II                 | 31 (72)           | 21 (70)              | 10 (77) |
| Class III                | 7 (16)            | 5 (17)               | 2 (15) |
| Primary tumor status     |                   |                      | 1.000  |
| Controlled               | 29 (67)           | 20 (67)              | 9 (69) |
| Uncontrolled             | 14 (33)           | 10 (33)              | 4 (31) |
| Extracranial metastases  |                   |                      | 1.000  |
| Absent                   | 12 (28)           | 8 (27)               | 4 (31) |
| Present                  | 31 (72)           | 22 (73)              | 9 (69) |
| Number of BM             | 0.491             |                      |        |
| ≤3                       | 14 (33)           | 11 (37)              | 3 (23) |
| >3                       | 29 (67)           | 19 (63)              | 10 (77) |
| Size of largest BM (mm)  | 22.07±10.91       | 24.51±11.74          | 16.45±5.89 | 0.024 |
| Hemorrhagic BM           | 0.019             |                      |        |
| No                       | 32 (74)           | 19 (63)              | 13 (100) |
| Yes                      | 11 (26)           | 11 (37)              | 0 (0)  |
| Total dose               | 0.310             |                      |        |
| ≤40 Gy2                  | 26 (60)           | 20 (67)              | 6 (46) |
| >40 Gy2                  | 17 (40)           | 10 (33)              | 7 (54) |
| EGFR TKI during RT       | 0.324             |                      |        |
| No                       | 24 (56)           | 15 (50)              | 9 (69) |
| Yes                      | 19 (44)           | 15 (50)              | 4 (31) |
| Type of EGFR TKI         | 1.000             |                      |        |
| Gefitinib                | 5 (26)            | 4 (27)               | 1 (25) |
| Erlotinib                | 14 (74)           | 11 (73)              | 3 (75) |
| Chemotherapy during RT   | 1.000             |                      |        |
| No                       | 33 (77)           | 23 (77)              | 10 (77) |
| Yes                      | 10 (23)           | 7 (23)               | 3 (23) |

Abbreviations: ECOG Eastern Cooperative Oncology Group, RPA recursive partitioning analysis, BM brain metastases, Gy2 biologically equivalent dose equal to fraction size of 2 Gy, TKI tyrosine kinase inhibitor. Categorical data were presented as number (percentage) and continuous data were presented as mean ± standard deviation.
1.14–19.12; \( p = 0.032 \)). There was no significant association between radiographic response and treatment modalities such as RT dose and the use of concurrent systemic chemotherapy or EGFR TKI.

### Outcome and survival

There were no ≥grade-3 RT-related toxicities in patients treated with brain RT alone, but 4 patients experienced major toxicities (grade-3 acneiform rash in 2 patients, grade-3 oral mucositis in 1 patient, and grade-3 otitis media in 1 patient) during the course of concurrent EGFR TKI use. To minimize brain edema, oral or intravenous corticosteroids were administered in 39 patients (91%) during the course of brain RT, and tapered off thereafter. After a median follow-up of 15 months (range: 3–39 months), 33 patients had died. Three died of intracranial disease progression, 22 of extracranial disease progression, and 8 of other causes (4 with pneumonia, 1 with urosepsis, 1 with intra-abdominal infection, 1 with upper gastrointestinal bleeding, and 1 with stroke). The median overall survival was 15 months (95% CI: 9.61–20.39 months). The univariate analysis showed that EGFR mutations (\( p = 0.061 \)) and performance status (\( p = 0.076 \)) had a borderline impact in predicting OS (Additional file 2: Table S2). The median OS for patients with or without EGFR mutations was 15 and 11 months, respectively (Figure 1A). Multivariable analyses did not reveal any other clinical characteristics significantly associated with OS.

Forty-one patients (95%) had at least 2 consecutive follow-up images. Eleven patients (26%) were found to have intracranial recurrence. The median intracranial RPFS was 18 months (95% CI: 8.33–27.68 months). Table 3 summarizes the association between different variables and intracranial RPFS. Multivariable analyses revealed that EGFR mutations (hazard ratio: 0.20, 95% CI: 0.05–0.81; \( p = 0.025 \)) and lower RPA class (\( p = 0.026 \)) are two predictors for longer intracranial RPFS. The median intracranial RPFS was 21 months for patients with EGFR mutations and 12 months for those without (Figure 1B). Also illustrated in Figure 1B, the 1-year RPFS for patients with or without EGFR mutations was 66% and 0% (\( p = 0.009 \)), respectively.

### Discussion

Our study intended to address the relationship between EGFR mutations and RT response in NSCLC, and concluded that NSCLC with mutant EGFR is more sensitive to brain RT in patients with brain metastases. Although EGFR overexpression is associated with radioresistance in cancer [13-16], EGFR mutations in NSCLC have been shown to confer radiosensitivity in vitro [17].

### Table 2: Univariate and multivariable analyses of clinical characteristics in predicting radiographic response to brain RT

| Characteristics | Univariate analysis | Multivariable analyses |
|-----------------|---------------------|------------------------|
| Age, years (≧60 vs. <60) | 0.48 (0.13 to 1.81) | 0.277 |
| Gender (male vs. female) | 0.98 (0.27 to 3.61) | 0.975 |
| Smoking history (ever vs. never) | 0.93 (0.24 to 3.54) | 0.911 |
| EGFR mutation status (positive vs. negative) | 4.67 (1.14 to 19.12) | 0.032 |
| Mutant EGFR† (exon 21 vs. exon 19) | 0.42 (0.06 to 2.77) | 0.369 |
| ECOG performance status | 0.73 (0.34 to 1.56) | 0.415 |
| RPA class | | |
| I (reference) | 1 | – |
| II | 0.00 (0.00 to ∞) | 1.000 |
| III | 0.00 (0.00 to ∞) | 1.000 |
| Primary tumor status (uncontrolled vs. controlled) | 1.12 (0.28 to 4.57) | 0.869 |
| Extracranial metastases (present vs. absent) | 2.05 (0.51 to 8.34) | 0.314 |
| Number of BM (≧3 vs. <3) | 0.89 (0.22 to 3.61) | 0.869 |
| Size of largest BM (mm) | 1.07 (0.99 to 1.15) | 0.091 |
| Hemorrhagic BM (yes vs. no) | 6.00 (0.68 to 52.90) | 0.107 |
| Total dose (≧40 Gy\(_2\) vs. ≦40 Gy\(_2\)) | 1.07 (0.28 to 4.05) | 0.925 |
| EGFR TKI during RT (yes vs. no) | 0.89 (0.24 to 3.30) | 0.864 |
| Type of EGFR TKI§ (erlotinib vs. gefitinib) | 1.67 (0.20 to 14.05) | 0.639 |
| Chemotherapy during RT (yes vs. no) | 2.00 (0.36 to 11.06) | 0.427 |

**Abbreviations:** OR odds ratio, CI confidence interval, ECOG Eastern Cooperative Oncology Group, RPA recursive partitioning analysis, BM brain metastases, Gy\(_2\) biologically equivalent dose equal to fraction size of 2 Gy, TKI tyrosine kinase inhibitor.

† \( n = 30 \).

§ \( n = 19 \).
Figure 1 Survival of non-small cell lung cancer patients with brain metastases treated with brain RT stratified by EGFR mutation status. (A) Overall survival. (B) Intracranial radiological progression-free survival (RPFS). Censored cases is marked by cross sign "+".
cell lines with exon 19 deletions or L858R point mutation exhibit characteristics of radiosensitive phenotype, such as delayed double-strand DNA break repair and increased radiation-induced apoptosis. The radiosensitivity is independent of mutations in p53 or at EGFR residue 790 (T790M). Upon irradiation, the clonogenic survival for NSCLCs with EGFR mutations is reduced by up to 500- to 1000-fold, as compared with those with the wild-type. Clinically, previous research on the relationship between EGFR mutations in NSCLC and the response to brain RT has discrepant findings. One study reported that NSCLC patients with mutant EGFR have a significantly higher response rate to whole brain RT than those with wild-type EGFR (54% vs. 24%; \( p = 0.045 \)), judged by the interval change of neurological symptoms, performance status, and the use of corticosteroids [19]. Nevertheless, another study showed no significant difference in brain RT response among NSCLC patients with and without EGFR mutations (67% vs. 50%; \( p = 0.23 \)) by assessing at least 1 post-treatment brain MRI scan [18]. By using regular intracranial imaging follow-ups, our study demonstrated that NSCLC patients with EGFR mutations have a higher radiographic response rate. The image-based intracranial response rate for patients with mutant EGFR was approximately 2-fold higher than that for the wild-type group (80% vs. 46%; \( p = 0.037 \)).

In this study, we also found that NSCLC with mutant EGFR is associated with prolonged intracranial RPFS (21 vs. 12 months; \( p = 0.009 \)) in patients with brain metastases, as compared with wild-type EGFR. This result echoes previous finding that the median time to intracranial progression is longer in NSCLC patients with EGFR mutations than in those without (12.4 vs. 8.4 months; \( p = 0.39 \)), judged by incidental findings of brain MRI [18]. Our study not only demonstrates the same trend by consecutive follow-up images but also suggests that the superior radiosensitivity in patients with mutant EGFR might contribute to a longer intracranial RPFS. In NSCLC patients with wild-type EGFR, more aggressive intracranial treatment for brain metastases, such as stereotactic radiosurgery or neurosurgical excision, should be considered, owing to the inferior treatment outcome of conventional brain RT. Furthermore, our study showed that a lower pre-treatment RPA class is associated with a longer intracranial RPFS \( (p = 0.026) \), but does not affect OS \( (p = 0.295) \). This finding is different from prior studies [6-8,12], in which a lower pre-treatment RPA class was associated with superior response.

### Table 3: Univariate and multivariable analyses of clinical characteristics in predicting intracranial radiological progression-free survival

| Characteristics | Univariate analysis | Multivariable analyses |
|-----------------|---------------------|------------------------|
|                 | HR 95% CI of HR P   | HR 95% CI of HR P      |
| Age, years (≧60 vs. <60) | 1.07 0.35 to 3.32 0.904 | 1               |
| Gender (male vs. female) | 1.27 0.42 to 3.84 0.673 | 0.577   |
| Smoking history(ever vs. never) | 1.59 0.51 to 4.94 0.419 | 0.587   |
| EGFR mutation status (positive vs. negative) | 0.20 0.05 to 0.77 0.020 | 0.20 0.05 to 0.81 0.025 |
| Mutant EGFR† (exon 21 vs. exon 19) | 1.49 0.40 to 5.61 0.555 | 0.555   |
| ECOG performance status | 1.66 0.84 to 3.27 0.144 | 0.144   |
| RPA class | 0.022‡ | 0.026‡ |
| Class I (reference) | 1 | – – |
| Class II | 3.00 0.37 to 24.43 0.306 | 2.54 0.30 to 21.36 0.390 |
| Class III | 12.67 1.18 to 136.31 0.036 | 12.26 1.08 to 138.65 0.043 |
| Primary tumor status (uncontrolled vs. controlled) | 1.46 0.37 to 5.80 0.588 | 0.588   |
| Extracranial metastases (present vs. absent) | 0.71 0.23 to 2.19 0.549 | 0.549   |
| Number of BM (>3 vs. ≦3) | 1.02 0.33 to 3.14 0.970 | 0.970   |
| Size of largest BM (mm) | 1.01 0.97 to 1.05 0.560 | 0.560   |
| Hemorrhagic BM (yes vs. no) | 0.76 0.23 to 2.58 0.664 | 0.664   |
| Total dose (>40 Gy2 vs. ≦40 Gy2) | 0.86 0.23 to 3.28 0.825 | 0.825   |
| EGFR TKI during RT (yes vs. no) | 1.32 0.44 to 3.97 0.620 | 0.620   |
| Type of EGFR TKI§ (erlotinib vs. gefitinib) | 1.39 0.16 to 11.98 0.764 | 0.764   |
| Chemotherapy during RT (yes vs. no) | 0.95 0.26 to 3.46 0.940 | 0.940   |

Abbreviations: HR hazard ratio, CI confidence interval, ECOG Eastern Cooperative Oncology Group, RPA recursive partitioning analysis, BM brain metastases, Gy2 biologically equivalent dose equal to fraction size of 2 Gy, TKI tyrosine kinase inhibitor.

† n = 30.
‡ n = 19.
§ P for linear trend.
OS. This discrepancy might be explained by selection bias in our cohort. The majority of our patients (40 of 43) presented with adenocarcinoma and 70% had EGFR mutations. The median OS in our study was 15 months, which was longer than the 2 to 6 months reported in several previous studies [6-8,26-28]. This result echoes the findings of prior researches showing that adenocarcinoma [29] and EGFR mutations [18] are prognostic factors associated with long-term survival in lung cancer patients with brain metastases. In this patient subset, we showed that EGFR mutation status \((p = 0.061)\) and pretreatment performance status \((p = 0.076)\) had a trend to predict OS. With recent advances in the management of NSCLC as well as the popularity of biomarker assessment, we suggest routine assessment of EGFR mutation status to provide personalized therapy and predict treatment outcome.

On the other hand, our study did not show a superior response to brain RT in NSCLC patients treated concurrently with an EGFR TKI \((p = 0.864)\), despite the synergistic effect shown by previous studies [19,30]. In experimental models, the use of an EGFR TKI in combination with RT has been shown to increase antitumor activity by amplifying radiation-induced apoptosis and inhibiting tumor angiogenesis [30]. In one retrospective study, patients with concurrent EGFR TKI use were found to have a superior response rate to brain RT [19]. However, pharmacokinetic analyses of EGFR TKIs report that only a tiny percentage (as low as 1%) of EGFR TKIs can penetrate into the cerebrospinal fluid, even in patients with brain metastases [31,32]. Therefore, an adequate EGFR TKI concentration for growth inhibition of mutant EGFR NSCLC cells might not be achieved in the brain by standard-dose EGFR TKI administration [33]. Thus, the clinical impact of combining an EGFR TKI with brain RT remains uncertain. In addition, variation in EGFR mutations might affect individual responses to EGFR TKI [34]. Although our retrospective study did not demonstrate a synergistic effect, it highlighted that future prospective trials are needed to elucidate the combined effect of EGFR TKIs and brain RT.

Due to the stringent inclusion criteria and retrospective nature of this study, the patient number was relatively small and most of the patients received a variety of treatments. Despite this weakness, there was a substantial difference between the survival curves of patients with and without EGFR mutations. In addition, possible discordance in EGFR expression between metastatic and primary tumors should be considered, since the majority of our samples used for EGFR mutation testing were from primary tissues. In NSCLC, disparities in EGFR mutations between metastatic and primary tumors were shown to have an 8.75% to 28% discordance rate [35-38]. However, it is not feasible to obtain brain tumor samples for genotyping in every patient with brain metastases. Recent advances in molecular imaging technologies such as positron emission tomography might be helpful for \textit{in vivo} detection of EGFR distribution or activation in future studies [39,40]. Further prospective studies are imperative to clarify the degree of mutant EGFR that affects treatment outcome in NSCLC patients with brain metastases.

### Conclusions

In summary, our results suggest that mutant EGFR in NSCLC patients is an independent prognostic factor for better treatment response and longer intracranial RPFS following RT for brain metastases. Therefore, before brain RT, identification of EGFR mutation status is helpful in predicting treatment outcome.

### Additional files

- **Additional file 1:** Table S1. Radiographic response after brain RT based on RECIST criteria and associated EGFR mutation status.
- **Additional file 2:** Table S2. Univariate analysis of clinical characteristics in predicting overall survival.

### Competing interests

The authors declare no competing interests.

### Authors’ contributions

HLL, TSC, and HLL provided the concept of the study and were involved in the study design, data analysis, writing and revision of the manuscript. HLL, TSC and LLT carried out all image evaluation and interpretation of the study. TSC, LLT, JTT, SWC, JFC and HWCL participated in clinical care and follow-up of the patients. All authors reviewed and approved the final manuscript.

### Acknowledgements

This work was supported in part by grants from Department of Health, Taiwan (DOH100-TD-C-111-008) for the Center of Excellence for Cancer Research, Taipei Medical University, Taipei, Taiwan.

### Author details

1. Department of Radiation Oncology, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan. 2. Department of Internal Medicine, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan. 3. Department of Radiation Oncology, Landseed Hospital, Pingtung, Taiwan. 4. Department of Radiation Oncology, Taipei Medical University Hospital, Taichung, Taiwan. 5. Department of Radiation Oncology, Taipei Medical University-Shuang Ho Hospital, Taipei, Taiwan. 6. Department of Radiation Oncology, China Medical University Hospital, Taichung, Taiwan. 7. Graduate Institute of Clinical Medicine, Taipei Medical University, 250 Wushing Street, Taipei, Taiwan.

Received: 9 May 2012 Accepted: 13 October 2012

### References

1. Merchut MP: Brain metastases from undiagnosed systemic neoplasms. \textit{Arch Intern Med} 1989, 149:1076–1080.
2. Parkin DM, Bray F, Ferlay J, et al: \textit{Global cancer statistics, 2002}. \textit{CA Cancer J Clin} 2005, 55:74–108.
3. Young K: \textit{Palliation of brain and spinal cord metastases}. In \textit{Penz and Brady’s Principles and Practice of Radiation Oncology}. 5th edition. Philadelphia, USA: Lippincott Williams & Wilkins; 2008:1974–1985.
4. Andrews DW, Scott CB, Spreutus PW, et al: \textit{Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to
three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet 2004, 363:1665–1672.

5. Gaspar L, Scott C, Rotman M, et al: Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys 1997, 37:745–751.

6. Gaspar LE, Scott C, Murray K, et al: Validation of the RTOG recursive partitioning analysis (RPA) classification for brain metastases. Int J Radiat Oncol Biol Phys 2000, 47:1001–1006.

7. Kepka L, Cieslak E, Bujko K, et al: Results of the whole-brain radiotherapy for patients with brain metastases from lung cancer: the RTOG RPA intra-class analysis. Acta Oncol 2005, 44:389–398.

8. Mehta MP, Tsao MN, Whelan TJ, et al: The American Society for Therapeutic Radiology and Oncology (ASTRO) evidence-based review of the role of radiosurgery for brain metastases. Int J Radiat Oncol Biol Phys 2005, 63:37–46.

9. Kocher M, Soffritti R, Abacioglu U, et al: Adjunct whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: Results of the EORTC 22952-26001 study. J Clin Oncol 2011, 29:134–141.

10. Saito EY, Viani GA, Fenzlino R, et al: Whole brain radiation therapy in management of brain metastases: results and prognostic factors. Radiat Oncol 2006, 1:20.

11. Sperduto PW, Chao ST, Seidt PK, et al: Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases: a multi-institutional analysis of 4,259 patients. J Radiat Oncol Biol Phys 2010, 77:655–661.

12. Sperduto PW, Kased N, Roberge D, et al: Radiotherapy in lung adenocarcinoma with epidermal growth factor receptor mutations on clinical response. J Clin Cancer Res 2009, 15:247–255.

13. Das AK, Sato M, Story MD, et al: The epidermal growth factor receptor mediates radioresistance. Int J Radiat Oncol Biol Phys 2003, 57:246–254.

14. Sheridan MT, O'Dwyer T, Seymour CB, et al: Potential indicators of radiosensitivity in squamous cell carcinoma of the head and neck. Radiat Oncol Invest 1997, 5:1081–1086.

15. Liang K, Ang KK, Milas L, et al: The expression of epidermal growth factor receptor results in a worse prognosis for patients with rectal cancer treated with preoperative radiotherapy: a multicenter, retrospective analysis. Radiat Oncol 2005, 74:101–108.

16. Liang K, Ang KK, Milas L, et al: The epidermal growth factor receptor status as an independent predictor of cancer-specific survival in non-small cell lung cancer. J Clin Oncol 2009, 27:3093–3100.

17. Eisenhauer EA, Therasse P, Bogaerts J, et al: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009, 45:288–307.

18. Sperduto PW, Chao ST, Seidt PK, et al: Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases: a multi-institutional analysis of 4,259 patients. J Radiat Oncol Biol Phys 2010, 77:655–661.

19. Sperduto PW, Kased N, Roberge D, et al: Radiotherapy in lung adenocarcinoma with epidermal growth factor receptor mutations on clinical response. J Clin Cancer Res 2009, 15:247–255.

20. Liang K, Ang KK, Milas L, et al: The epidermal growth factor receptor mediates radioresistance. Int J Radiat Oncol Biol Phys 2003, 57:246–254.

21. Sheridan MT, O’Dwyer T, Seymour CB, et al: Potential indicators of radiosensitivity in squamous cell carcinoma of the head and neck. Radiat Oncol Invest 1997, 5:1081–1086.

22. Liang K, Ang KK, Milas L, et al: The expression of epidermal growth factor receptor results in a worse prognosis for patients with rectal cancer treated with preoperative radiotherapy: a multicenter, retrospective analysis. Radiat Oncol 2005, 74:101–108.

23. Liang K, Ang KK, Milas L, et al: The epidermal growth factor receptor status as an independent predictor of cancer-specific survival in non-small cell lung cancer. J Clin Oncol 2009, 27:3093–3100.

24. Eisenhauer EA, Therasse P, Bogaerts J, et al: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009, 45:288–307.

25. Trott C, Colevas AD, Setera A, et al: CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 2003, 13:176–181.

26. Kosaka T, Yatake Y, Endoh H, et al: Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res 2004, 64:8919–8923.

27. Sonobe M, Manabe T, Wada H, et al: Mutations in the epidermal growth factor receptor gene are linked to smoking-independent, lung adenocarcinoma. Br J Cancer 2006, 93:355–363.

28. Tam YM, Chung LP, Suen WS, et al: Distinct epidermal growth factor receptor and KRAS mutation patterns in non-small cell lung cancer patients with different tobacco exposure and clinicopathologic features. Clin Cancer Res 2006, 12:1647–1653.

29. Bergqvist M, Brattström D, Brunstaker H, et al: Irradiation of brain metastases from lung cancer: a retrospective study. Lung Cancer 1998, 20:57–63.

30. Lagerwaard FJ, Levendag PC, Nowak PJ, et al: Identification of prognostic factors in patients with brain metastases: a review of 1292 patients. Int J Radiat Oncol Biol Phys 1999, 43:795–803.

31. Rodriguez P, de Brouwer P, Raymakers E: Brain metastases and non-small cell lung cancer, prognostic factors and correlation with survival after irradiation. Lung Cancer 2001, 32:129–136.

32. Noteman J, Hildebrand J, Roemans P, et al: Long-term survival after surgery of solitary cerebral metastasis of lung cancer. Clinical case and review of the literature. Neurochirurgie 1990, 36:308–311.

33. Huang SM, Li JJ, Armstrong EA, et al: Modulation of radiation response and tumor-induced angiogenesis after epidermal growth factor receptor inhibition by ZD1839 (Iressa). Cancer Res 2002, 62:4300–4306.

34. Jackman DM, Holmes AJ, Lindeman N, et al: Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib. J Clin Oncol 2008, 26:4517–4520.

35. Lassman AB, Rossi MR, Raizer JJ, et al: Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: tissue analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01. Clin Cancer Res 2005, 11:7841–7850.

36. Clarke JL, Pao W, Wu N, et al: High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer. J Neurooncol 2010, 99:283–286.

37. Yang CH, Yu CJ, Shih JY, et al: Specific EGFR mutations predict treatment outcome of stage IIIb/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy. J Clin Oncol 2008, 26:2745–2753.

38. Gow CH, Chang YL, Hsu YC, et al: Comparison of epidermal growth factor receptor mutations between primary and corresponding metastatic tumors in tyrosine kinase inhibitor-naive non-small-cell lung cancer. Ann Oncol 2009, 20:696–702.

39. Kalikaki A, Kourtoupolou A, Trypaki M, et al: Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC. Br J Cancer 2008, 99:923–929.

40. Park S, Holmes-Tisch AJ, Cho EY, et al: Discordance of molecular biomarkers associated with epidermal growth factor receptor pathway between primary tumors and lymph node metastasis in non-small cell lung cancer. J Thorac Oncol 2009, 4:817–819.

41. Sun L, Zhang Q, Luan H, et al: Comparison of KRAS and EGFR gene status between primary non-small cell lung cancer and local lymph node metastases: implications for clinical practice. J Exp Clin Cancer Res 2011, 30:30.

42. Mishani E, Hagaoly A: Strategies for molecular imaging of epidermal growth factor receptor tyrosine kinase in cancer. J Nucl Med 2009, 50:1199–1202.

43. Pantaleo MA, Nannini M, Maleddu A, et al: Experimental results and related clinical implications of PET detection of epidermal growth factor receptor (EGFR) in cancer. Ann Oncol 2009, 20:213–226.

Cite this article as: Lee et al.: EGFR mutations are associated with favorable intracranial response and prolonged survival following brain irradiation in non-small cell lung cancer patients with brain metastases. Radiation Oncology 2012 7:181.

doi:10.1186/1748-717X-7-181